Partner Andrea Abascal and associate Andrés Sepúlveda, from our Life Sciences practice, published this article for the International Bar Association, analyzing access to orphan drugs in markets like Chile. Despite progress in local research, clinical trial, and the emergence of and orphan drug registry, the lack of comprehensive regulation remains the main obstacle to ensuring access. Proper regulation would not only improve availability but also help reduce the significant cost borne by the State, as many patients have resorted to legal action to obtain treatment, ultimately forcing the government to cover the expenses.

Full article here: https://www.ibanet.org/orphan-drugs-chile